Thirona contributes to the progress of cystic fibrosis by using quantitative imaging to help researchers better understand structural lung disease.
Public source
Publisher name
Public post
Cystic fibrosis affects more than 100,000 people worldwide. Once considered a fatal childhood disease, CF has seen remarkable progress. Earlier diagnosis and treatments…
Company
Thirona
AI-powered lung image analysis
- Industry
- Hospitals and Health Care
- Location
- Nijmegen, NL
- Company size
- 51–200 employees
About Thirona
Thirona is a global company specializing in advanced AI-powered analysis of thoracic imaging. Built on robust segmentation and precise quantification of bronchial, parenchymal, and vascular lung structures, the LungQ® portfolio delivers automated, accurate assessments across pulmonary diseases. Validated in 200+ peer-reviewed publications, LungQ® provides reliable, reproducible results spanning diverse populations and disease severities. Developed in collaboration with research institutes, academic hospitals, pharmaceutical innovators, and MedTech partners, Thirona’s solutions are used to accelerate imaging-based respiratory clinical trials and advance minimally invasive interventions. Today, LungQ® is installed in 1,200+ hospitals worldwide, contributing to progress in precision medicine for lung disease.
See moreLatest activity
Latest activity from Thirona
6 signals
Presence & Recognition
Thirona contributed to the discussion on how quantitative CT can help extract more information from bronchiectasis at the Open Source Imaging Consortium Annual Meeting at the ERS2026 International Congress.
Research & Knowledge
Thirona published findings from the 10-year COPDGene study showing that LungQ® automated measurements demonstrated a strong association between longitudinal airway changes and COPD progression with significantly higher mucus plug burden observed over time in patients with progressive disease.
Presence & Recognition
Thirona's Chief Innovation Officer Jean-Paul Charbonnier, PhD will explore how AI-based quantitative CT analysis of bronchiectasis can provide deeper insights into chronic airway disease at the upcoming OSIC Annual Meeting.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Brainomix
Brainomix published research findings exploring the potential of its lung imaging biomarkers to predict future FVC decline and clinical trials.
Research & Knowledge
Zimmer Biomet EMEA
Zimmer Biomet EMEA published a study showing that lung nodule detection at Massachusetts General Hospital achieved 94% accuracy, catching fatigue and volume.
Research & Knowledge
electronRx
electronRx pairs a smartphone-based measurement returning respiratory function in around sixty seconds backed by a 644-subject investigation across the UK and Japan with a platform architected for multiple chronic conditions.
Research & Knowledge
COPD Foundation
COPD Foundation published a study in the latest issue of Chronic Obstructive Pulmonology: Journal of the COPD Foundation that captured 4 lung sound measurements from individuals to create an acoustic map representing COPD physiology.
Research & Knowledge
American College of Chest Physicians